FierceBiotech

On Medtronic's tail, Axonics scores FDA nod for 15-year neurostim implant for incontinence

The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...
FierceBiotech

Axonics kicks off U.S. launch of recharge-free sacral neuromodulation implant

Barely a month after winning FDA clearance for its long-lasting implant to treat bladder dysfunction, Axonics is wasting no time in bringing the device to the masses. The Southern California-based ...
MD&M East

Axonics Closes a Portfolio Gap in Sacral Neuromodulation

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
Business Wire

Axonics Announces First Fecal Incontinence Patients Implanted with Its Miniaturized Rechargeable Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Nasdaq

Axonics® Launches ARTISTRY Study to Collect and Analyze Real-World Data of Patients Implanted with the Axonics r-SNM System

ARTISTRY will enroll up to 300 patients across 30 centers in North America and include patients across all four clinical indications for Axonics Therapy IRVINE, Calif.--(BUSINESS WIRE)-- Axonics ...
Nasdaq

U.S. Patent Office Completes Review of Medtronic Patents, Rejects More Axonics Challenges

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark ...